Key Points
- Insider sale: Sumita Ray sold 8,829 Cue Biopharma shares for approximately $265,665, reducing her holdings by 6.93% to 118,545 shares. The sale was made to cover tax withholding related to vested equity awards.
- Weak financial results: Cue Biopharma reported a quarterly loss of $24.14 per share, substantially missing the $1.69 consensus estimate, despite revenue of $7.88 million exceeding expectations of $3 million.
- Negative market sentiment: The stock was down 19.2%, and analysts maintained an overall “Sell” rating. Institutional investors own 35.04% of the company, while Cue Biopharma continues developing cancer and infectious-disease immunotherapies.
Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) VP Michael Vincent Meluzio sold 5,628 shares of the firm's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $169,346.52. Following the completion of the transaction, the vice president directly owned 48,961 shares of the company's stock, valued at approximately $1,473,236.49. The trade was a 10.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Cue Biopharma Stock Performance
Cue Biopharma stock opened at $27.64 on Tuesday. The stock has a market cap of $116.09 million, a P/E ratio of -1.02 and a beta of 2.47. Cue Biopharma, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $45.50. The firm's fifty day moving average price is $29.47 and its 200-day moving average price is $143.72.
Cue Biopharma (NASDAQ:CUE - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analysts' expectations of $3.00 million. Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.
Analyst Upgrades and Downgrades
CUE has been the subject of a number of research analyst reports. Wall Street Zen downgraded Cue Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Cue Biopharma in a research report on Thursday. One analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma presently has a consensus rating of "Sell".
View Our Latest Analysis on Cue Biopharma
Institutional Investors Weigh In On Cue Biopharma
Large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new stake in Cue Biopharma during the second quarter worth about $337,755,000. Bank of America Corp DE bought a new position in shares of Cue Biopharma during the 2nd quarter valued at about $219,000. ADAR1 Capital Management LLC bought a new position in shares of Cue Biopharma during the 2nd quarter valued at about $1,742,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Cue Biopharma during the 2nd quarter valued at about $83,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cue Biopharma during the 2nd quarter valued at about $722,000. Hedge funds and other institutional investors own 35.04% of the company's stock.
Cue Biopharma Company Profile
(
Get Free Report)
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
